Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Generate Biomedicines
Comprehensive Cancer Center Munich (CCCM)
Celgene
University of South Florida
Indiana University
Columbia University
Bayer